Intermediate conductance calcium-activated potassium channel (KCa3.1) in cancer: Emerging roles and therapeutic potentials

被引:0
|
作者
Van, Nhung Thi Hong [1 ,2 ]
Nam, Joo Hyun [1 ,2 ]
机构
[1] Dongguk Univ, Coll Med, Dept Physiol, Gyeongju 38066, South Korea
[2] Dongguk Univ, Coll Med, Channelopathy Res Ctr CRC, Goyang 10326, South Korea
关键词
KCa3.1; KCNN4; Cancer progression; Metastasis; Tumor microenvironment; Biomarker; Cancer therapeutic target; CA2+-ACTIVATED K+ CHANNEL; T-CELL-ACTIVATION; GARDOS CHANNEL; K(CA)3.1 CHANNELS; BREAST-CANCER; UP-REGULATION; IN-VITRO; TUMOR MICROENVIRONMENT; PROGNOSTIC BIOMARKER; CHLORIDE SECRETION;
D O I
10.1016/j.bcp.2024.116573
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The KCa3.1 channel (also known as the KCNN4, IK1, or SK4 channel) is an intermediate-conductance calciumactivated potassium channel that regulates the membrane potential and maintains calcium homeostasis. Recently, KCa3.1 channels have attracted increasing attention because of their diverse roles in various types of cancers. In cancer cells, KCa3.1 channels regulate key processes, including cell proliferation, cell cycle, migration, invasion, tumor microenvironments, and therapy resistance. In addition, abnormal KCa3.1 expression in cancers is utilized to distinguish between tumor and normal tissues, classify cancer stages, and predict patient survival outcomes. This review comprehensively examines the current understanding of the contribution of KCa3.1 channels to tumor formation, metastasis, and its mechanisms. We evaluated the potential of KCa3.1 as a biomarker for cancer diagnosis and prognosis. Finally, we discuss the advances and challenges of applying KCa3.1 modulators in cancer treatment and propose approaches to overcome these obstacles. In summary, this review highlights the importance of this ion channel as a potent therapeutic target and prognostic biomarker of cancer.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Role of the calcium-activated K+ channel KCa3.1 in the progression of pancreatic ductal adenocarcinoma
    Soret, B.
    Petho, Z.
    Lehen'kyi, V.
    Schwab, A.
    ACTA PHYSIOLOGICA, 2022, 236 : 687 - 689
  • [32] The role of the intermediate conductance calcium-activated potassium channel IK in breast cancer
    Mohr, C. J.
    Steudel, F. A.
    Lo, W. Y.
    Stegen, B.
    Huber, S. M.
    Hoppe, R.
    Schroth, W.
    Brauch, H.
    Ruth, P.
    Lukowski, R.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2017, 390 : S64 - S65
  • [33] Mapping the binding site of NS309, a superagonistic positive gating modulator for the calcium-activated potassium channel KCa3.1
    Nasburg, Joshua A.
    BIOPHYSICAL JOURNAL, 2023, 122 (03) : 252A - 252A
  • [34] Mapping the binding site of NS309, a superagonistic positive gating modulator for the calcium-activated potassium channel KCa3.1
    Nasburg, Joshua
    Shim, Heesung
    Wulff, Heike
    BIOPHYSICAL JOURNAL, 2022, 121 (03) : 246A - 246A
  • [35] Augmenting the activity of calcium-activated potassium channel KCa3.1 revitalizes T-cell function in the immunosuppressive tumor microenvironment
    Verma, Navin K.
    Wong, Brandon Han Siang
    Ong, Seow Theng
    Goay, Stephanie Shee Min
    Ho, Ying Swan
    Chen, Shuwen
    Bi, Xuezhi
    Shim, Heesung
    Wulff, Heike
    Webster, Richard D.
    Shelat, Vishalkumar G.
    Chandy, K. George
    BIOPHYSICAL JOURNAL, 2023, 122 (03) : 256A - 256A
  • [36] Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis
    Köhler, R
    Wulff, H
    Eichler, I
    Kneifel, M
    Neumann, D
    Knorr, A
    Grgic, I
    Kämpfe, D
    Si, H
    Wibawa, J
    Real, R
    Borner, K
    Brakemeier, S
    Orzechowski, HD
    Reusch, HP
    Paul, M
    Chandy, KG
    Hoyer, J
    CIRCULATION, 2003, 108 (09) : 1119 - 1125
  • [37] Pharmacological roles of the large-conductance calcium-activated potassium channel
    Wu, Sheng-Nan
    Wu, Adonis Z.
    Lin, Ming-Wei
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (10) : 1025 - 1030
  • [38] Cardiovascular phenotype of intermediate-conductance KCa-channel(KCa3.1)-knockout mice.
    Koehler, Ralf
    Heyken, Willm-Thomas
    Si, Han
    Grgic, Ivica
    Hoyer, Joachim
    FASEB JOURNAL, 2007, 21 (05): : A539 - A539
  • [39] Intermediate-Conductance Ca2+-Activated K+ Channel, KCa3.1, as a Novel Therapeutic Target for Benign Prostatic Hyperplasia
    Ohya, Susumu
    Niwa, Satomi
    Kojima, Yoshiyuki
    Sasaki, Shoichi
    Sakuragi, Motomu
    Kohri, Kenjiro
    Imaizumi, Yuji
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 338 (02): : 528 - 536
  • [40] Intermediate-conductance Ca2+-activated K+ channel, KCa3.1 as a novel therapeutic target for benign prostatic hyperplasia
    Niwa, Satomi
    Ohya, Susumu
    Kojima, Yoshiyuki
    Sasaki, Shoichi
    Sakuragi, Motomu
    Kohri, Kenjiro
    Imaizumi, Yuji
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 94P - 94P